Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).

Authors

Liqiong Xue

Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

Liqiong Xue , Kunyu Yang , Meiyu Fang , Xuelei Ma , Wen Zou , Muran Ding , Zhaoxiang Wang , Yujia Peng , Sa Xiao , Hongwei Wang , Hai Zhu , Martin Sebastian Olivo , Yi Zhu , Ye Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first‑line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

First Author: Lori J. Wirth

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.

First Author: A. Dimitrios Dimitrios Colevas

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

First Author: Douglas Adkins

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.

First Author: Christine H. Chung